当前位置: 首页 >> 检索结果
3752. Detection of anti-eIF2B autoantibodies in systemic sclerosis by immunoprecipitation-mass spectrometry.
作者: Jean-Baptiste Vulsteke.;Frédéric Coutant.;David Goncalves.;Benoit Nespola.;Petra De Haes.;Wim A Wuyts.;Daniel Blockmans.;Ellen De Langhe.;Nicole Fabien.;Xavier Bossuyt.
来源: Rheumatology (Oxford). 2023年62卷7期e216-e218页 3753. The incidence of Kawasaki disease using hospital admissions data for England 2006-2021.
作者: Myron Odingo.;Megan Rutter.;Jonathan Bowley.;Emily J Peach.;Peter C Lanyon.;Matthew J Grainge.;Peter Stillwell.;Sean McPhail.;Mary Bythell.;Jeanette Aston.;Sarah Stevens.;Rachael McCormack.;Paul Brogan.;Fiona A Pearce.
来源: Rheumatology (Oxford). 2023年62卷9期3117-3125页
To describe the incidence of Kawasaki Disease (kDa) between 2006 and 2021 in England.
3754. Dose-response relationships of tea and coffee consumption with gout: a prospective cohort study in the UK Biobank.
作者: Huangda Guo.;Siyue Wang.;Hexiang Peng.;Mengying Wang.;Liming Li.;Jie Huang.;Tao Wu.
来源: Rheumatology (Oxford). 2023年62卷9期3043-3050页
The association of tea or coffee consumption with gout is inconsistently reported. Few prospective studies have explored their dose-response relationship. Therefore, we aimed to quantitatively investigate the association between tea, coffee and the risk of developing gout.
3756. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.
作者: Md Yuzaiful Md Yusof.;Jack Arnold.;Benazir Saleem.;Claire Vandevelde.;Shouvik Dass.;Sinisa Savic.;Edward M Vital.;Paul Emery.
来源: Lancet Rheumatol. 2023年5卷2期e88-e98页
Concerns have been raised regarding the reduced immunogenicity of vaccines against COVID-19 in patients with autoimmune diseases treated with rituximab. However, the incidence and severity of breakthrough infections in unbiased samples of patients with specific rheumatic and musculoskeletal diseases are largely unknown. We aimed to assess the incidence of breakthrough SARS-CoV-2 infection, compare rates of moderate-to-severe COVID-19 with any severe infection event, and evaluate predictors of moderate-to-severe COVID-19 outcomes in patients treated with rituximab.
3757. Reduced digestion of circulating genomic DNA in systemic sclerosis patients with the DNASE1L3 R206C variant.
作者: Brian Skaug.;Xinjian Guo.;Yuanteng Jeff Li.;Julio Charles.;Kay T Pham.;Jacob Couturier.;Dorothy E Lewis.;Claudia Bracaglia.;Ivan Caiello.;Maureen D Mayes.;Shervin Assassi.
来源: Rheumatology (Oxford). 2023年62卷9期3197-3204页
Polymorphism in a coding region of deoxyribonuclease I-like III (DNASE1L3), causing amino acid substitution of Arg-206 to Cys (R206C), is a robustly replicated heritable risk factor for SSc and other autoimmune diseases. DNASE1L3 is secreted into the circulation, where it can digest genomic DNA (gDNA) in apoptosis-derived membrane vesicles (AdMVs). We sought to determine the impact of DNASE1L3 R206C on digestion of circulating gDNA in SSc patients and healthy controls (HCs).
3758. Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis.
作者: Michael Kreuter.;Francesco Bonella.;Norbert Blank.;Gabriela Riemekasten.;Ulf Müller-Ladner.;Jörg Henes.;Elise Siegert.;Claudia Günther.;Ina Kötter.;Christiane Pfeiffer.;Marc Schmalzing.;Gabriele Zeidler.;Peter Korsten.;Laura Susok.;Aaron Juche.;Margitta Worm.;Ilona Jandova.;Jan Ehrchen.;Cord Sunderkötter.;Gernot Keyßer.;Andreas Ramming.;Tim Schmeiser.;Alexander Kreuter.;Kathrin Kuhr.;Hanns-Martin Lorenz.;Pia Moinzadeh.;Nicolas Hunzelmann.
来源: Rheumatology (Oxford). 2023年62卷9期3067-3074页
Gastroesophageal reflux disease (GERD) occurs frequently in patients with SSc. We investigated whether the presence of GERD and/or the use of anti-acid therapy, specifically proton-pump inhibitors (PPIs), are associated with long-term outcomes, especially in SSc-associated interstitial lung disease (SSc-ILD).
3760. Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: a case-control study.
作者: Tsz On Lam.;Isaac T Cheng.;Steven H Lam.;Chi Chiu Mok.;Carmen T Ho.;Tommy T Cheung.;Virginia W Lao.;Hin Ting Pang.;Chi Hung To.;Cheuk Wan Yim.;Alexandra Ng.;Kitty Y Kwok.;Ka Lai Lee.;Shirley K Ying.;Man Choi Wan.;Jolly M Lee.;Lai-Shan Tam.
来源: Rheumatology (Oxford). 2023年62卷9期2998-3005页
This study explored whether the excess cardiovascular (CV) disease (CVD) risk in RA could be ameliorated by suppression of inflammation using a treat-to-target (T2T) approach. We compared the CV event (CVE) incidence among ERA patients managed by a T2T strategy with a CV risk factor-matched non-RA population and a historical RA cohort (HRA).
|